En Carta Diagnostics Overview
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
9
En Carta Diagnostics General Information
Description
Developer of a biotechnology platform designed for molecular diagnostics through synthetic biology. The company's platform offers ready-to-use tests against validated targets, as well as in-house development of new tools against virtually any DNA or RNA target using its patented technologies, enabling healthcare professionals to easily detect and identify infections.
Contact Information
Website
www.encarta.bioCorporate Office
- 6 Rue Jean Calvin
- 75005 Paris
- France
Corporate Office
- 6 Rue Jean Calvin
- 75005 Paris
- France
En Carta Diagnostics Timeline
En Carta Diagnostics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 7. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 6. Seed Round | 22-May-2024 | Completed | Generating Revenue | |||
| 5. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 4. Seed Round | 16-Aug-2022 | Completed | Generating Revenue | |||
| 3. Accelerator/Incubator | 10-May-2022 | Completed | Startup | |||
| 2. Accelerator/Incubator | Completed | Startup | ||||
| 1. Accelerator/Incubator | 16-Sep-2020 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
En Carta Diagnostics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
En Carta Diagnostics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
En Carta Diagnostics Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| CentraleSupélec | Accelerator/Incubator | Minority | ||
| CVS Health | Corporation | Minority | ||
| Skysong Innovations | Accelerator/Incubator | |||
| Wilco(Paris) | Accelerator/Incubator | |||
| Creative Destruction Lab | Accelerator/Incubator |
En Carta Diagnostics FAQs
-
Where is En Carta Diagnostics headquartered?
En Carta Diagnostics is headquartered in Paris, France.
-
What is the size of En Carta Diagnostics?
En Carta Diagnostics has 10 total employees.
-
What industry is En Carta Diagnostics in?
En Carta Diagnostics’s primary industry is Diagnostic Equipment.
-
Is En Carta Diagnostics a private or public company?
En Carta Diagnostics is a Private company.
-
What is En Carta Diagnostics’s current revenue?
The current revenue for En Carta Diagnostics is .
-
How much funding has En Carta Diagnostics raised over time?
En Carta Diagnostics has raised $1.64M.
-
Who are En Carta Diagnostics’s investors?
CentraleSupélec, CVS Health, Skysong Innovations, Wilco(Paris), and Creative Destruction Lab are 5 of 9 investors who have invested in En Carta Diagnostics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
